Exobiosphere Wins Almost €1m Investment on ‘Meet the Drapers’

On Wednesday 1 April 2026, Luxembourg-based biotechnology company, Exobiosphere, secured an investment of approximately €0.87 ($1) million on “Meet the Drapers”, a globally broadcast venture capital competition created and hosted by an American venture capital investor, Tim Draper.

Announced in the season finale, which aired on Monday 31 March 2026, the company emerged as the winner after competing against thousands of applicants worldwide and advancing through three rounds. The organisers presented the outcome as a notable development for the space and life sciences sector.

Exobiosphere develops space-based biomedical research technologies. Its Orbital High-Throughput Screening (OHTS) platform enables pharmaceutical and biotechnology partners to conduct automated, large-scale compound screening and disease modelling in microgravity, generating data that cannot be replicated under Earth conditions.

Commenting on the result, Exobiosphere CEO, Kyle Acierno, said: “This investment from Tim Draper and the Meet the Drapers platform is a tremendous validation of what we’re building at Exobiosphere. Tim Draper has a track record of recognising transformative ideas before they become mainstream, and we’re honoured that he sees the potential in what we’re building.”

Tim Draper commented: “They feel like they’ve got an advantage in what best affects cancer in space.”

Rob Solomon, First Judge, said: “The hundred-times improvement is remarkable. But what really stood out to me is the transition of cells into 3D - I didn’t know that was possible. That opens up incredible opportunities to understand and study them at a much deeper level. It’s something that just makes a lot of sense.”

Adam Draper, Second Judge, noted: “Pharma is already trying to run experiments in space - that’s real. But it’s been extremely limited because you actually have to go up to the ISS. Even basic processes become complicated - things just float away. It sounds almost absurd, but that’s the reality scientists deal with.”

Commenting on the project, the company noted that microgravity plays a central role in Exobiosphere’s research model. In this environment, cells can behave more naturally and disease models can become more physiologically accurate. Researchers have also observed accelerated progression of certain neurodegenerative conditions, allowing scientists to study disease development and treatment responses over shorter periods compared to Earth-based laboratories.

The company’s platform is designed to run more than 2,000 automated experiments per mission in a standardised format, with the aim of making space-based research scalable and accessible to pharmaceutical and biotechnology partners.

This latest achievement builds on a series of developments for Exobiosphere over the past year, including winning Boryung’s Human in Space Challenge and the Startup World Cup Luxembourg, securing contracts with Cedars-Sinai and the University of Notre Dame, and confirming a launch on Haven-1, a commercial space station planned by Vast.

Founded in Luxembourg, Exobiosphere operates internationally with offices in Los Angeles and Houston in the United States.